* If you want to update the article please login/register
Acute bacterial sinusitis is a common diagnosis for which antibiotics are prescribed to outpatients. Some types of bacteria that cause sinusitis are resistant to penicillin and certain other classes of antibiotics, but may be treatable with antibiotic levofloxacin. This will be an open - label, multi - center, non - comparative clinical trial involving patients with protocol - defined acute bacterial sinusitis suitable for treatment with oral antibiotics. At the Preliminary Visit, sinus radiograph will be obtained to confirm clinical diagnosis of sinusitis, and investigators will perform a nasal exam. Sinus puncture and placement of indwelling sinus catheter into affected maxillary sinus will be performed on all eligible patients at first visit. Patients meeting study criteria will receive 750 milligrams of levofloxacin tablets once daily for 5 days. The primary objective is to establish the rate and extent of bacteriological eradication, defined as eradication of pathogens from maxillary sinus, and to establish the effectiveness and safety of once - daily 750 milligrams levofloxacin for treatment of acute bacterial sinusitis in adults. Levofloxacin 750 milligram tablet orally once day for 5 days
A Systematic review was undertaken with MEDLINE search for antibiotics and indications. Include studies that meet the following criteria: original study; random allocation to treatment groups; treatment with one of the following oral antibiotics - moxifloxacin, Levofloxacin, ciprofloxacin, gatifloxacin; control by either placebo or active comparator medication; Double - blind, single - blind or open treatment; men and women; Diagnosis of one of three indications; and treatment duration of at least three days. Outcome measures include efficacy and safety. Comparative and single arm meta - analyses were conduct. Statistical differences in antibiotic success rates were evaluate. Pool point estimates and 95% CIs for comparative statistics and single - arm analysis were examined to evaluate equivalence. All clinical studies were identified by systematic review of literature in PubMed, EMBASE, and Cochrane Databases until September 2018 using the following search terms: Levofloxacin, bacterial, pneumonia, sinusitis, urinary tract infections, and random *. Only randomized control trials that compared clinical efficacy and adverse effect of high - dose, short - course Levofloxacin and conventional regimen were include. In addition, we search all references in relevant articles and reviews for additional eligible studies. Conference abstracts were not search. Studies were excluded if they focussed on in vitro activity or Pharmacokinetic - pharmacodynamics assessment only. Articles of all languages of publication were include. Two authors search and examine publications independently to avoid bias. When they disagree, another author resolves the issue. Following data including year of publication, study design and duration, type of infections, antibiotic regimen of Levofloxacin, and comparator, outcomes, and adverse effects were extracted from every included study. A comprehensive literature search for all published clinical trials of antibiotics used in treatment of CAP, AECB and SIN was conduct. Unpublished studies were obtained from Bayer Canada Inc. Search of MEDLINE was conducted using the following MEDLINE search strategy: moxifloxacin, levofloxacin, ciprofloxacin, gatifloxacin,'sinusitis, bronchitis, pneumonia and community - acquire infections. Search was limited to human, English, clinical trials; clinical trial - phase 3; clinical trial - phase 4; control clinical trial; meta - analysis; multicentre study; or randomized control trial. Manual cross - referencing and bibliographic searches of review articles were also conduct. Papers were rat for inclusion criteria. To be included in meta - analysis, each study meet following inclusion criteria: original study; random allocation to treatment groups; treatment with one of the following oral antibiotics - moxifloxacin, Levofloxacin, ciprofloxacin and gatifloxacin; control by either placebo or active comparator medication; Double - blind, single - blind or open - label treatment; all patients, males and females, were 18 years of age or older; Diagnosis of mild To moderate CAP, AECB or SIN; and treatment duration of at least three days. All nonrandomized and nonclinical trial study designs were excluded from meta - analysis to decrease bias. Epidemiological studies, abstracts, noncomparator studies, dose - finding studies, Pharmacokinetic studies and single dose studies were excluded from analysis. Clinical success rate was considered the primary outcome variable in the analysis. Success rate was defined as the proportion of patients who had successful outcome and / or responded to treatment.
Amoxicillin and Levaquin are antibiotics used to treat various bacterial infections of the throat, lungs, skin, prostate, and bladder. Amoxicillin is penicillin while Levaquin belongs to class of antibiotics called fluoroquinolones. Penicillins and fluoroquinolones work differently in killing bacteria. Both drugs have similar side effects, for example, abdominal pain, headache, rash, itching, insomnia, Diarrhea, nausea, and vomiting. Amoxicillin also causes side effects that include easy bruising, heartburn, insomnia, confusion, bleeding, and dizziness. Levaquin has serious side effects, for example, sun sensitivity, low blood sugar, high blood sugar, abnormal heart beats, l iver problems, C. Diff associate Diarrhea. Dosage depends upon the drug and type of infection. Amoxicillin has few drug interactions while Levaquin interacts with certain mineral supplements, nonsteroidal anti - inflammatory drugs, and blood thinners like warfarin. Neither drug is recommended to take if you are pregnant or breastfeeding.
Levofloxacin is a broad - spectrum, third - generation fluoroquinolone antibiotic used to treat bacterial infections. Levofloxacin is a safe and effective medicine on the World Health Organization's essential medicines list. It was patented in 1987 and subsequently received FDA - approval in 1996 for medical use in the United States. Levofloxacin is FDA - approved for treatment of nosocomial pneumonia, community - acquired pneumonia, acute bacterial rhinosinusitis, acute bacterial exacerbation of chronic bronchitis, prostatitis, acute pyelonephritis, urinary tract infection, skin or skin structure infections, prophylaxis and treatment of plague due to Yersinia pestis, and TO reduce incidence of disease progression of inhalational anthrax. Due to increased risk of severe side effects, levofloxacin is used only in patients with acute exacerbation of chronic bronchitis, acute bacterial sinusitis, and uncomplicated urinary tract infections, who do not have alternative treatment options. Ophthalmic levofloxacin is also used in the treatment of bacterial conjunctivitis. To decrease development of drug - resistant bacteria, FDA has recommended using levofloxacin only for strongly suspected bacterial infections. Also, levofloxacin should not be used empirically in patients at risk of multidrug - resistant Escherichia coli.
Bacterial antibiotic resistance is a significant problem in Richmond, Virginia, and throughout the United States. Many common bacteria that can cause sinusitis carry gene for antibiotic resistance that can be turned on in the presence of antibiotics. After a few days of treatment, gene becomes activated and can even travel between bacteria, creating resistance among large populations of bacteria. If you do not respond to a course of antibiotics within 4 - 7 days, you may have resistant strain of bacteria. Consult your physician for examination and possible culture or DNA analysis of your sinuses. Dna analysis of sinus drainage allows us to identify the most dangerous resistant strains within 24 hours and to provide complete analysis of all bacteria in your nose within 1 week.
Completing its initial phases of drug development in the mid 1990s as one of the first Fluoroquinolones that could be used with confidence to treat respiratory tract infections, Levofloxacin went on to become one of the most widely prescribed antibiotics in the world. Available in both oral and intravenous formulations and with characteristics of over 90% bioavailability, distribution into both extracellular and intracellular pulmonary compartments, highly predictable pharmacokinetics with over 90% of the drug being excrete unchanged in urine, and reliable activity against a broad spectrum of clinically important pathogens, Levofloxacin has been use successfully To treat patients with variety of serious Infectious Diseases as well as common infections Most often treated outside of hospital setting. Results of clinical trials involving patients with respiratory tract, urinary tract, and skin infections have consistently shown rates of clinical success and bacteriological Eradication that were comparable to other widely used broad - spectrum agents. Regimens of Levofloxacin, initially involving total daily doses of 250 mg to 500 mg, but more recently regimens involving 750 mg doses, have been shown to be safe and effective. Nearly a decade and half of clinical experience has defined safety and tolerability profile that permit data - driven assessment of risks and benefits of using Levofloxacin. As resistance to currently available fluoroquinolones has emerge, clinical value of Levofloxacin deserves continued evaluation. However, consistently high rates of susceptibility of clinically important bacteria, especially among those bacteria that commonly cause respiratory tract infections, such as Streptococcus pneumoniae and Haemophilus influenzae, suggest that this agent will continue to be widely used well past the 20 - year anniversary of its introduction into the antibacterial armamentarium. Levofloxacin is a member of the fluoroquinolone class of antibacterial agents with microbiological activity against clinically relevant bacteria that cause respiratory, skin and skin structure, and genitourinary tract infections. In the United States, Levofloxacin is currently indicated for treatment of respiratory tract infections, including acute bacterial exacerbations of chronic bronchitis, acute bacterial sinusitis, and community - acquire and nosocomial pneumonia; complicated and uncomplicated skin and skin structure infections; Post - inhalational anthrax; and genitourinary infections including uncomplicated and complicated urinary tract infections, acute pyelonephritis, and chronic prostatitis. 1 Similar indications have been approved for Levofloxacin in Europe and Asia. As understanding of pharmacodynamics and drug's safety and tolerability evolve, clinical trials have been conducted with several dose regimens. Initial work largely assessed regimens involving not more than 500 mg daily dose: 250 mg dose regimens for patients with urinary tract infections and 500 mg dose regimens for respiratory tract infections. Higher dose regimens involving 750 mg doses were subsequently studied in patients with skin and skin structure infections 2 and in patients with nosocomial pneumonia. 3 Most Recently, higher - dose 750 mg dose regimens given over shorter courses were studied in patients with respiratory tract infections, as potential for this modification to favorably impact drug resistance became apparent.
Researchers first discovered this family of antibiotics in the 1960s, but it wasnt until the late 1980s that Cipro and other modern fluoroquinolones first hit the market. At time, doctors primarily prescribe medications to treat urinary tract infections. Since then, they have become go - to antibiotics for many infections. In fact, American doctors write about 29. 7 million fluoroquinolone antibiotic prescriptions in 2016, according to the Centers for Disease Control and Prevention most current statistics. These drugs are potent, and the US Food and Drug Administration approved them to treat or prevent serious bacterial infections, including anthrax, plague and bacterial pneumonia. A 2016 FDA safety review found antibiotics are associated with disabling side effects involving tendons, muscles, joints, nerves and central nervous system. These side effects can occur hours to weeks after exposure to drugs and may potentially be permanent, according to the Agency. Most severe side effects of fluoroquinolones are considered rare. Some can be fatal. Medications carry FDA's most serious warning, black box warning, for tendinitis, tendon rupture, peripheral neuropathy, central nervous system effects and exacerbation of myasthenia gravis. In December 2018, FDA required new warning about the increased risk of aortic ruptures or tears that can lead to dangerous bleeding or even death. People who suffered aortic injuries after taking fluoroquinolones have filed lawsuits over Cipro, Levaquin and Avelox. Because of the risks, FDA has announced that patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis and uncomplicated urinary tract infections should only use these medications when no alternative treatment options exist. As with other antibacterial drugs, fluoroquinolones do not treat viral infections such as colds, flu or bronchitis in people who are otherwise healthy. They should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria, according to drugs label. This is to reduce development of drug - resistant bacteria and to maintain the effectiveness of antibacterial drugs. Dr. Lindsey R. Baden, Infectious Disease doctor at Brigham and Womens Hospital, agrees with the FDA. She told Consumer Reports that doctors often overprescribe fluoroquinolones because they work against many types of bacteria. Fluoroquinolones play an important role in treating serious infections such as those caused by bacteria that are resistant to other types of antibiotics, Baden told Consumer Reports. But in case of less serious infections, they should typically be reserved for second - line or even third - line treatment after other antibiotics have fail, she say.
Amoxicillin or amoxicillin / clavulanate are recommended for initial empirical therapy for acute bacterial sinusitis in adults. 2. High doses of amoxicillin or amoxicillin / clavulanate should be considered for patients in areas with high prevalence of penicillin - resistant S. Pneumoniae, patients with severe symptoms, older patients, patients with recent hospital admission, patients with a history of antimicrobial therapy within the past month, and immunocompromised patients. 3. Patients allergic to penicillin: for patients with type 4 hypersensitivity, doxycycline or fluoroquinolones or third - generation cephalosporins or clindamycin may be consider. For type 1 hypersensitivity, all beta - lactam antibiotics should not be used. Non - beta - lactam antibiotics should be used 4. Empirical antibiotic therapy should be maintained for a short period unless patient has severe acute sinusitis.
Levaquin is the second most popular drug in the class. From 2004 to 2010, Americans received about 88. 1 million prescriptions for levofloxacin, according to the FDA Office of Surveillance and Epidemiology. It is a third - generation fluoroquinolone. Fda originally approved the drug in 1996. In 2010, it was the best - selling antibiotic in the United States, according to the New York Times. Like Cipro, it treats respiratory and urinary tract infections. It also treats other conditions, including plague, anthrax, bronchitis and pneumonia. Janssen Pharmaceuticals stopped making Levaquin, according to FDA, though the agency does not specify why the drugmaker discontinued it. Although company discontinue all versions of brand - name drug in December 2017, it may still be available in pharmacies until 2020, according to news outlet RTV6 in Indianapolis. The decision to discontinue Levaquin was made due to the wide availability of alternative treatment options, and our focus on developing innovative medicines designed to address unmet medical patient needs, Kelsey Buckholtz, spokeswoman for Janssen, told RTV6.
Zithromax may interact with blood thinners, cyclosporine, other antibiotics, theophylline, cholesterol - lowering medicines, heart medications, HIV medicines, sedatives or seizure medicines. Zithromax may also interact with arsenic trioxide, pimozide, tacrolimus, antidepressants, anti - malaria medications, ergot medicines, blood pressure medications, medicine to prevent or treat nausea and vomiting, medicines to treat psychiatric disorders, migraine headache medicines, narcotics, or tranquilizers. Levaquin may interact with blood thinners, antibiotics, antidepressants, anti - malaria medications, medicine to prevent or treat nausea and vomiting, medicines to treat psychiatric disorders, migraine headache medicines, nonsteroidal anti - inflammatory drugs, steroids, or narcotics. Levaquin may also interact with antacids that contain magnesium or aluminum, sucralfate, didanosine, vitamins or mineral supplements that contain iron or zinc, insulin or oral diabetes medications, or theophylline. The typical oral dose of Zithromax consists of 500 mg for 1 day then 250 mg for 4 days. The typical intravenous dose consists of 500 mg for 2 days followed by 500 mg orally daily for an additional 5 - 8 days. Take LEVAQUIN exactly as your healthcare provider tells you to take it. Take LEVAQUIN at about the same time each day. Drink plenty of fluids while you take LEVAQUIN. Take LEVAQUIN Oral Solution 1 hour before or 2 hours after eating. If you miss dose of LEVAQUIN, take it as soon as you remember. Do not take more than 1 dose in 1 day. Do not skip any doses of LEVAQUIN or stop taking it, even if you begin to feel better, until you finish your prescribed treatment unless: you have tendon problems. See what is the most important information I should know about LEVAQUIN?. You have serious allergic reaction. See what are possible side effects of LEVAQUIN?. Your healthcare provider tell you to stop taking LEVAQUIN Taking all of your LEVAQUIN doses will help make sure that all of the bacteria are kill. Taking all of your LEVAQUIN doses will help you lower the chance that bacteria will become resistant to LEVAQUIN. If your infection does not get better while you take LEVAQUIN, it may mean that bacteria causing your infection may be resistant to LEVAQUIN. If your infection does not get better, call your healthcare provider. If your infection does not get better, LEVAQUIN and other similar antibiotic medicines may not work for you in the future. If you take too much LEVAQUIN, call your healthcare provider or get medical help right away. Zithromax Z - PAK and LEVAQUIN are antibiotics used to treat Bacterial Infections. Zithromax and LEVAQUIN belong to different antibiotic drug classes. Zithromax is a macrolide antibiotic and LEVAQUIN is a fluoroquinolone antibiotic. Zithromax may interact with blood thinners, cyclosporine, other antibiotics, theophylline, cholesterol - lowering medicines, heart medications, HIV medicines, sedatives or seizure medicines. Zithromax may also interact with arsenic trioxide, pimozide, tacrolimus, antidepressants, anti - malaria medications, ergot medicines, blood pressure medications, medicine to prevent or treat nausea and vomiting, medicines to treat psychiatric disorders, migraine headache medicines, narcotics, or tranquilizers.
Fluoroquinolones have been associated with disabling and Potentially Irreversible Serious Adverse Reactions that have occur together including: Tendinitis and Tendon Rupture, Peripheral Neuropathy, and CNS Effects. Discontinue Drugs immediately and avoid use of Systemic fluoroquinolones in Patients who experience any of these Serious Adverse Reactions. May exacerbate muscle weakness in patients with Myasthenia Gravis; fluoroquinolones should be avoided in patients with a known history of Myasthenia Gravis. Both oral and injectable fluroquinolones are associated with disabling side effects involving tendons, muscles, joints, nerves and Central Nervous System. These side effects can occur hours to weeks after exposure to fluoroquinolones and may potentially be permanent because the risk of these serious side effects generally outweighs benefits for patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated UTIs, that fluoroquinolones should be reserved for use in Patients with these conditions who have no alternative treatment options For some Serious bacterial infections, including anthrax, plague, and bacterial pneumonia among others, benefits of fluoroquinolones outweigh risks and it is appropriate For them to remain available as therapeutic option this medication contain Levofloxacin. Do not take LEVAQUIN or Levofloxacin Systemic if you are allergic to Levofloxacin or any ingredients contained in this drug. Keep out of reach of children. In case of overdose, get medical help or contact the Poison Control Center immediately. This drug may cause liver damage. Call your doctor right away if you have any signs of liver problems. Symptoms can include nausea or vomiting, stomach pain, fever, weakness and, abdominal pain or tenderness. They can also include itching, unusual tiredness, loss of appetite, light - colored bowel movements, dark - colored urine, and yellowing of your skin or whites of your eyes. Tell your doctor right away if you have a fast or irregular heartbeat or if you faint. This drug may cause a rare heart problem called QT Interval Prolongation. This serious condition can cause abnormal heartbeat. Your risk may be higher if youre senior, have a family history of QT Prolongation, have hypokalemia, or take certain drugs to control your heart rhythm. This drug can cause suicidal thoughts or behaviors. Your risk is greater if you have a history of depression. Call your doctor right away if you have thoughts of harming yourself while taking this drug. Levofloxacin can cause severe allergic reaction,ss even after only one dose. Symptoms can include: hives, trouble breathing or swallowing, swelling of your lips, tongue, face, throat tightness or hoarseness, fast heart rate, fainting skin Rash If you have an allergic reaction, call your doctor or local Poison Control Center right away. If your symptoms are severe, call 911 or go to the nearest emergency room. Dont take this drug again if youve ever had allergic reaction to it. Taking it again could be fatal. For People with diabetes: People who take Levofloxacin with diabetes drugs or insulin can develop low blood sugar or high blood sugar. Severe problems, such as comas and death, have been reported as a result of hypoglycemia.
Headache, hunger, sweating, irritability, dizziness, nausea, fast heart rate, feeling anxious or shaky, numbness or tingling in your hands, arms, legs or feet, weakness in your arms, hands, legs or feet, burning pain in your arms, hands, legs or feet, serious mood or behavioral changes, nervousness, confusion, agitation, paranoia, hallucinations, memory problems, trouble concentrating, thoughts of suicide, tendon rupture, sudden pain, swelling, bruising, tenderness, stiffness, movement problems, snapping or popping sound in any of your joints, severe stomach pain, Diarrhea that is watery or bloody, fluttering in your chest, shortness of breath, skin Rash, breathing problems, seizures, severe headaches, vision problems, pain behind your eyes, upper stomach pain, loss of appetite, dark urine, clay - colored stools, and yellowing of skin or eyes get medical help right away, if you have any of symptoms list above. Nausea, Constipation, Diarrhea, Headache, Dizziness, and trouble sleeping. Tell doctor if you have any side effects that bother you or that do not go away. These are not all possible side effects of Levaquin. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to TO FDA at 1 - 800 - FDA - 1088.
There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects when subject differences in creatinine clearance are taken into consideration. Following 500 mg oral dose of LEVAQUIN to healthy elderly subjects, mean terminal plasma elimination half - life of levofloxacin was about 7. 6 hours, as compared to approximately 6 hours in younger adults. The difference was attributable to variation in renal function status of subjects and was not believed to be clinically significant. Drug absorption appears to be unaffected by age. Levaquin dose adjustment based on age alone is not necessary.
Plex.page is an Online Knowledge, where all the summarized are written by a machine. We aim to collect all the knowledge the World Wide Web has to offer.
© All rights reserved
2021 made by Algoritmi Vision Inc.
If your domain is listed as one of the sources on any summary, you can consider participating in the "Online Knowledge" program, if you want to proceed, please follow these instructions to apply.
However, if you still want us to remove all links leading to your domain from Plex.page and never use your website as a source, please follow these instructions.